> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Outlines Concerns with Unapproved GLP-1 Drugs
- URL: https://www.fdaweb.com/fda-outlines-concerns-with-unapproved-glp-1-drugs/
- Published: 2025-03-18T12:00:00.000Z
- Updated: 2026-09-14T14:55:35.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158845

An FDA drug safety notice says the agency is aware that some patients and healthcare providers may look to unapproved versions of glucagon-like peptide-1 (GLP-1) receptor agonists as an option for weight loss. “This can be risky for patients,” the [notice](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?ref=fdaweb.com) says, “as unapproved versions do not undergo FDA’s review for safety, effectiveness, and quality before they are marketed.” The post discusses these issues:

- concerns with compounded versions of the drugs; and
- illegally marketed versions of these drugs.